Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy
The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy. 79 patients with ischemic cardiomyopathy were prospectively enroll...
Gespeichert in:
| Veröffentlicht in: | Journal of nuclear cardiology 2020-02, Vol.27 (1), p.269-279 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 279 |
|---|---|
| container_issue | 1 |
| container_start_page | 269 |
| container_title | Journal of nuclear cardiology |
| container_volume | 27 |
| creator | Ko, Kuan-Yin Wang, Shan-Ying Yen, Ruoh-Fang Shiau, Yu-Chien Hsu, Jung-Cheng Tsai, Hao-Yuan Lee, Chien-Lin Chiu, Kuan-Ming Wu, Yen-Wen |
| description | The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy.
79 patients with ischemic cardiomyopathy were prospectively enrolled for dynamic cardiac FDG PET, and then followed for at least 6 months. Perfusion-metabolism patterns were determined based on visual score analysis of 201Tl SPECT and FDG PET. MRGlu was analyzed using the Patlak kinetic model. The primary end-point was cardiovascular mortality. Significantly higher MRGlu was observed in viable compared with non-viable areas. Negative correlations were found between MRGlu in transmural match and a history of hyperlipidemia, statin usage, and triglyceride levels. Diabetic patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) had a significantly lower MRGlu in transmural match, mismatch, and reverse mismatch. Patients with MRGlu in transmural match ≥ 23.40 or reverse mismatch ≥ 36.90 had a worse outcome.
Myocardial glucose utilization was influenced by substrates and medications, including statins and DPP4i. MRGlu could discriminate between viable and non-viable myocardium, and MRGlu in transmural match and reverse mismatch may be prognostic predictors of cardiovascular death in patients with ischemic cardiomyopathy. |
| doi_str_mv | 10.1007/s12350-018-1395-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2088757123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071358123017658</els_id><sourcerecordid>2358711358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-939c4f15f5c5dd99a7ad86e93536d4215198adf3276ac9e3862a59d7f25dd3f3</originalsourceid><addsrcrecordid>eNp9kctqHDEQRUWIiR0nH5BNEGSTTcd6tLolsgpDXmDwxnsh6zEj0y2NJbXD-OtTQzsJZDEbqaDOvVXURegdJZ8oIeNVpYwL0hEqO8qV6PoX6IIKzrpBCPoSajLSjgtJz9HrWu8JIYor9Qqdc0KJEopfoP1miilaM-EatykGKJP1OAf8sJjUYjMtPnpsavW1zj61Y2s7LTZXj5cWp_gERE44JryHCoiKf8W2w7HanZ-jxdYUF_N8yNDfHd6gs2Cm6t8-_5fo9tvX282P7vrm-8_Nl-vO9oK1Dha1faAiCCucU8qMxsnBKy744HpGBVXSuMDZOBirPJcDM0K5MTDAeeCX6ONquy_5YfG16RkW8tNkks9L1YxIOYoRDgjoh__Q-7yUBMtpOK8cKYX3JAVeknCqeqDoStmSay0-6H2JsykHTYk-ZqbXzDRkpo-Z6aPm_bPzcjd791fxJyQA2ApUaKWtL_9Gn3L9vIo8HPkxgqhaSMd6F4u3TbscT6h_AxWktb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2088803194</pqid></control><display><type>article</type><title>Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Ko, Kuan-Yin ; Wang, Shan-Ying ; Yen, Ruoh-Fang ; Shiau, Yu-Chien ; Hsu, Jung-Cheng ; Tsai, Hao-Yuan ; Lee, Chien-Lin ; Chiu, Kuan-Ming ; Wu, Yen-Wen</creator><creatorcontrib>Ko, Kuan-Yin ; Wang, Shan-Ying ; Yen, Ruoh-Fang ; Shiau, Yu-Chien ; Hsu, Jung-Cheng ; Tsai, Hao-Yuan ; Lee, Chien-Lin ; Chiu, Kuan-Ming ; Wu, Yen-Wen</creatorcontrib><description>The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy.
79 patients with ischemic cardiomyopathy were prospectively enrolled for dynamic cardiac FDG PET, and then followed for at least 6 months. Perfusion-metabolism patterns were determined based on visual score analysis of 201Tl SPECT and FDG PET. MRGlu was analyzed using the Patlak kinetic model. The primary end-point was cardiovascular mortality. Significantly higher MRGlu was observed in viable compared with non-viable areas. Negative correlations were found between MRGlu in transmural match and a history of hyperlipidemia, statin usage, and triglyceride levels. Diabetic patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) had a significantly lower MRGlu in transmural match, mismatch, and reverse mismatch. Patients with MRGlu in transmural match ≥ 23.40 or reverse mismatch ≥ 36.90 had a worse outcome.
Myocardial glucose utilization was influenced by substrates and medications, including statins and DPP4i. MRGlu could discriminate between viable and non-viable myocardium, and MRGlu in transmural match and reverse mismatch may be prognostic predictors of cardiovascular death in patients with ischemic cardiomyopathy.</description><identifier>ISSN: 1071-3581</identifier><identifier>EISSN: 1532-6551</identifier><identifier>DOI: 10.1007/s12350-018-1395-4</identifier><identifier>PMID: 30109593</identifier><language>eng</language><publisher>Cham: Elsevier Inc</publisher><subject>18F-fluorodeoxyglucose (FDG) ; Adult ; Aged ; Aged, 80 and over ; Cardiology ; Cardiomyopathy ; Clinical significance ; Cohort Studies ; Coronary artery disease ; Female ; Fluorodeoxyglucose F18 - pharmacokinetics ; Glucose ; Glucose - metabolism ; Heart failure ; Humans ; Imaging ; Male ; Medicine ; Medicine & Public Health ; Metabolism ; Middle Aged ; Myocardial glucose metabolism ; Myocardial Ischemia - diagnostic imaging ; Myocardial Ischemia - metabolism ; Myocardium - metabolism ; Nuclear Medicine ; Original Article ; Positron emission tomography (PET) ; Positron-Emission Tomography ; Radiology ; Radiopharmaceuticals - pharmacokinetics ; Tomography, Emission-Computed, Single-Photon</subject><ispartof>Journal of nuclear cardiology, 2020-02, Vol.27 (1), p.269-279</ispartof><rights>2020 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved.</rights><rights>American Society of Nuclear Cardiology 2018</rights><rights>Journal of Nuclear Cardiology is a copyright of Springer, (2018). All Rights Reserved.</rights><rights>2018© American Society of Nuclear Cardiology 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-939c4f15f5c5dd99a7ad86e93536d4215198adf3276ac9e3862a59d7f25dd3f3</citedby><cites>FETCH-LOGICAL-c452t-939c4f15f5c5dd99a7ad86e93536d4215198adf3276ac9e3862a59d7f25dd3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12350-018-1395-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12350-018-1395-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30109593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ko, Kuan-Yin</creatorcontrib><creatorcontrib>Wang, Shan-Ying</creatorcontrib><creatorcontrib>Yen, Ruoh-Fang</creatorcontrib><creatorcontrib>Shiau, Yu-Chien</creatorcontrib><creatorcontrib>Hsu, Jung-Cheng</creatorcontrib><creatorcontrib>Tsai, Hao-Yuan</creatorcontrib><creatorcontrib>Lee, Chien-Lin</creatorcontrib><creatorcontrib>Chiu, Kuan-Ming</creatorcontrib><creatorcontrib>Wu, Yen-Wen</creatorcontrib><title>Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy</title><title>Journal of nuclear cardiology</title><addtitle>J. Nucl. Cardiol</addtitle><addtitle>J Nucl Cardiol</addtitle><description>The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy.
79 patients with ischemic cardiomyopathy were prospectively enrolled for dynamic cardiac FDG PET, and then followed for at least 6 months. Perfusion-metabolism patterns were determined based on visual score analysis of 201Tl SPECT and FDG PET. MRGlu was analyzed using the Patlak kinetic model. The primary end-point was cardiovascular mortality. Significantly higher MRGlu was observed in viable compared with non-viable areas. Negative correlations were found between MRGlu in transmural match and a history of hyperlipidemia, statin usage, and triglyceride levels. Diabetic patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) had a significantly lower MRGlu in transmural match, mismatch, and reverse mismatch. Patients with MRGlu in transmural match ≥ 23.40 or reverse mismatch ≥ 36.90 had a worse outcome.
Myocardial glucose utilization was influenced by substrates and medications, including statins and DPP4i. MRGlu could discriminate between viable and non-viable myocardium, and MRGlu in transmural match and reverse mismatch may be prognostic predictors of cardiovascular death in patients with ischemic cardiomyopathy.</description><subject>18F-fluorodeoxyglucose (FDG)</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiology</subject><subject>Cardiomyopathy</subject><subject>Clinical significance</subject><subject>Cohort Studies</subject><subject>Coronary artery disease</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Glucose</subject><subject>Glucose - metabolism</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Myocardial glucose metabolism</subject><subject>Myocardial Ischemia - diagnostic imaging</subject><subject>Myocardial Ischemia - metabolism</subject><subject>Myocardium - metabolism</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Positron emission tomography (PET)</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><issn>1071-3581</issn><issn>1532-6551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kctqHDEQRUWIiR0nH5BNEGSTTcd6tLolsgpDXmDwxnsh6zEj0y2NJbXD-OtTQzsJZDEbqaDOvVXURegdJZ8oIeNVpYwL0hEqO8qV6PoX6IIKzrpBCPoSajLSjgtJz9HrWu8JIYor9Qqdc0KJEopfoP1miilaM-EatykGKJP1OAf8sJjUYjMtPnpsavW1zj61Y2s7LTZXj5cWp_gERE44JryHCoiKf8W2w7HanZ-jxdYUF_N8yNDfHd6gs2Cm6t8-_5fo9tvX282P7vrm-8_Nl-vO9oK1Dha1faAiCCucU8qMxsnBKy744HpGBVXSuMDZOBirPJcDM0K5MTDAeeCX6ONquy_5YfG16RkW8tNkks9L1YxIOYoRDgjoh__Q-7yUBMtpOK8cKYX3JAVeknCqeqDoStmSay0-6H2JsykHTYk-ZqbXzDRkpo-Z6aPm_bPzcjd791fxJyQA2ApUaKWtL_9Gn3L9vIo8HPkxgqhaSMd6F4u3TbscT6h_AxWktb8</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Ko, Kuan-Yin</creator><creator>Wang, Shan-Ying</creator><creator>Yen, Ruoh-Fang</creator><creator>Shiau, Yu-Chien</creator><creator>Hsu, Jung-Cheng</creator><creator>Tsai, Hao-Yuan</creator><creator>Lee, Chien-Lin</creator><creator>Chiu, Kuan-Ming</creator><creator>Wu, Yen-Wen</creator><general>Elsevier Inc</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20200201</creationdate><title>Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy</title><author>Ko, Kuan-Yin ; Wang, Shan-Ying ; Yen, Ruoh-Fang ; Shiau, Yu-Chien ; Hsu, Jung-Cheng ; Tsai, Hao-Yuan ; Lee, Chien-Lin ; Chiu, Kuan-Ming ; Wu, Yen-Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-939c4f15f5c5dd99a7ad86e93536d4215198adf3276ac9e3862a59d7f25dd3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>18F-fluorodeoxyglucose (FDG)</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiology</topic><topic>Cardiomyopathy</topic><topic>Clinical significance</topic><topic>Cohort Studies</topic><topic>Coronary artery disease</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Glucose</topic><topic>Glucose - metabolism</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Myocardial glucose metabolism</topic><topic>Myocardial Ischemia - diagnostic imaging</topic><topic>Myocardial Ischemia - metabolism</topic><topic>Myocardium - metabolism</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Positron emission tomography (PET)</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ko, Kuan-Yin</creatorcontrib><creatorcontrib>Wang, Shan-Ying</creatorcontrib><creatorcontrib>Yen, Ruoh-Fang</creatorcontrib><creatorcontrib>Shiau, Yu-Chien</creatorcontrib><creatorcontrib>Hsu, Jung-Cheng</creatorcontrib><creatorcontrib>Tsai, Hao-Yuan</creatorcontrib><creatorcontrib>Lee, Chien-Lin</creatorcontrib><creatorcontrib>Chiu, Kuan-Ming</creatorcontrib><creatorcontrib>Wu, Yen-Wen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nuclear cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ko, Kuan-Yin</au><au>Wang, Shan-Ying</au><au>Yen, Ruoh-Fang</au><au>Shiau, Yu-Chien</au><au>Hsu, Jung-Cheng</au><au>Tsai, Hao-Yuan</au><au>Lee, Chien-Lin</au><au>Chiu, Kuan-Ming</au><au>Wu, Yen-Wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy</atitle><jtitle>Journal of nuclear cardiology</jtitle><stitle>J. Nucl. Cardiol</stitle><addtitle>J Nucl Cardiol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>27</volume><issue>1</issue><spage>269</spage><epage>279</epage><pages>269-279</pages><issn>1071-3581</issn><eissn>1532-6551</eissn><abstract>The aim of this study was to prospectively quantify the rate of myocardial glucose uptake (MRGlu) in myocardium with different perfusion-metabolism patterns and determine its prognostic value in patients with ischemic cardiomyopathy.
79 patients with ischemic cardiomyopathy were prospectively enrolled for dynamic cardiac FDG PET, and then followed for at least 6 months. Perfusion-metabolism patterns were determined based on visual score analysis of 201Tl SPECT and FDG PET. MRGlu was analyzed using the Patlak kinetic model. The primary end-point was cardiovascular mortality. Significantly higher MRGlu was observed in viable compared with non-viable areas. Negative correlations were found between MRGlu in transmural match and a history of hyperlipidemia, statin usage, and triglyceride levels. Diabetic patients receiving dipeptidyl peptidase-4 inhibitors (DPP4i) had a significantly lower MRGlu in transmural match, mismatch, and reverse mismatch. Patients with MRGlu in transmural match ≥ 23.40 or reverse mismatch ≥ 36.90 had a worse outcome.
Myocardial glucose utilization was influenced by substrates and medications, including statins and DPP4i. MRGlu could discriminate between viable and non-viable myocardium, and MRGlu in transmural match and reverse mismatch may be prognostic predictors of cardiovascular death in patients with ischemic cardiomyopathy.</abstract><cop>Cham</cop><pub>Elsevier Inc</pub><pmid>30109593</pmid><doi>10.1007/s12350-018-1395-4</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1071-3581 |
| ispartof | Journal of nuclear cardiology, 2020-02, Vol.27 (1), p.269-279 |
| issn | 1071-3581 1532-6551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2088757123 |
| source | MEDLINE; SpringerNature Complete Journals |
| subjects | 18F-fluorodeoxyglucose (FDG) Adult Aged Aged, 80 and over Cardiology Cardiomyopathy Clinical significance Cohort Studies Coronary artery disease Female Fluorodeoxyglucose F18 - pharmacokinetics Glucose Glucose - metabolism Heart failure Humans Imaging Male Medicine Medicine & Public Health Metabolism Middle Aged Myocardial glucose metabolism Myocardial Ischemia - diagnostic imaging Myocardial Ischemia - metabolism Myocardium - metabolism Nuclear Medicine Original Article Positron emission tomography (PET) Positron-Emission Tomography Radiology Radiopharmaceuticals - pharmacokinetics Tomography, Emission-Computed, Single-Photon |
| title | Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A30%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20significance%20of%20quantitative%20assessment%20of%20glucose%20utilization%20in%20patients%20with%20ischemic%20cardiomyopathy&rft.jtitle=Journal%20of%20nuclear%20cardiology&rft.au=Ko,%20Kuan-Yin&rft.date=2020-02-01&rft.volume=27&rft.issue=1&rft.spage=269&rft.epage=279&rft.pages=269-279&rft.issn=1071-3581&rft.eissn=1532-6551&rft_id=info:doi/10.1007/s12350-018-1395-4&rft_dat=%3Cproquest_cross%3E2358711358%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2088803194&rft_id=info:pmid/30109593&rft_els_id=S1071358123017658&rfr_iscdi=true |